Table 4.
Univariate and Multivariate Logistic Regression Analysis of the Risk Factors of ≥3 RP
| Factor | Clinical Grades | Imaging Grades | ||||||
|---|---|---|---|---|---|---|---|---|
| Univariate Analysis | Multivariate Analysis | Univariate Analysis | Multivariate Analysis | |||||
| p value | OR (95% CI) | p value | OR (95% CI) | p value | OR (95% CI) | p value | OR (95% CI) | |
| Age | ||||||||
| <55 | ||||||||
| ≥55 | 0.352 | 1.439(0.668–3.099) | 0.164 | 1.774(0.792–3.976) | ||||
| Sex | ||||||||
| Male | ||||||||
| Female | 0.471 | 0.761(0.363–1.598) | 0.778 | 0.896(0.418–1.922) | ||||
| KPS | ||||||||
| >80 | ||||||||
| ≤80 | 0.915 | 1.043(0.482–2.259) | 0.987 | 0.993(0.448–2.202) | ||||
| Smoking index | ||||||||
| No | ||||||||
| Yes | 0.303 | 1.568(0.666–3.690) | 0.847 | 0.910(0.347–2.385) | ||||
| COPD | 0.044 | 3.019(1.033–8.830) | 0.006 | 4.424(1.542–12.693) | ||||
| Thoracic surgery | 0.388 | 0.514(0.114–2.326) | 0.446 | 0.556(0.122–2.521) | ||||
| Overlap time | ||||||||
| <30d | ||||||||
| ≥30d | 0.017 | 2.600(1.190–5.676) | 0.038 | 2.311(1.049–5.093) | ||||
| The timing of adding TRT after EGFR-TKIs use | ||||||||
| In the beginning of EGFR-TKIs use | 0.731 | 1.175(0.468–2.951) | 0.968 | 1.020(0.387–2.689) | ||||
| In the middle of EGFR-TKIs use | 0.725 | 1.144(0.540–2.426) | 0.899 | 0.951(0.436–2.074) | ||||
| In the progression after EGFR-TKIs use | 0.538 | 0.789(0.370–1.681) | 0.926 | 1.037(0.484–2.223) | ||||
| Type of mutation | ||||||||
| 19del | 0.626 | 0.828(0.389–1.766) | 0.342 | 0.682(0.309–1.503) | ||||
| L858R | 0.133 | 1.767(0.840–3.714) | 0.027 | 2.375(1.103–5.144) | ||||
| Area (lobe) | ||||||||
| Upper lobe | 0.854 | 1.072(0.512–2.245) | 0.853 | 931(0.437–1.983) | ||||
| Middle lobe | 0.827 | 0.904(0.365–2.241) | 0.985 | 0.991(0.397–2.473) | ||||
| Lower lobe | 0.997 | 0.998(0.433–2.303) | 0.820 | 1.103(0.474–2.564) | ||||
| Dose fractionation | ||||||||
| SBRT | ||||||||
| CFRT | 0.107 | 3.387(0.768–14.933) | 0.132 | 3.129(0.708–13.834) | ||||
| Radiationtherapy dose | ||||||||
| <53.15 | ||||||||
| ≥53.15 | 0.092 | 2.025(0.890–4.607) | 0.300 | 1.533(0.683–3.441) | ||||
| GTV | ||||||||
| <28.35 | ||||||||
| ≥28.35 | 0.014 | 2.708(1.219–6.015) | 0.047 | 0.416(0.175–0.987) | 0.002 | 4.221(1.731–10.292) | 0.007 | 3.686(1.420–9.564) |
| V5 | ||||||||
| <33.5 | ||||||||
| ≥33.5 | 0.102 | 1.862(0.885–3.919) | 0.050 | 2.149(1.002–4.613) | ||||
| V20 | ||||||||
| <17.5 | ||||||||
| ≥17.5 | 0.245 | 1.611(0.721–3.602) | 0.066 | 2.124(0.951–4.744) | ||||
| Grouping of 1G/2G/3G EGFR-TKIs | 0.910 | 1.026(0.658–1.599) | 0.642 | 1.113(0.709–1.746) | ||||
Note: The bold text was some risk factor of RP, which were significantly correlated with RP and the p value<0.05.
Abbreviations: CFRT, conventionally fractionated radiation therapy; COPD, Chronic obstructive pulmonary disease; d, days; GTV, Gross tumor volume; KPS, Karnofsky performance score; SBRT, stereotactic body radiation therapy; TRT, thoracic radiotherapy.